At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LEGN Legend Biotech
Closed 05-15 16:00:00 EDT
27.55
-1.05
-3.67%
盘后27.30
-0.25-0.91%
18:56 EDT
High28.42Low26.91Vol1.80M
Open28.12D1 Closing28.60Amplitude5.28%
Mkt Cap5.09BTradable Cap2.24BTotal Shares184.69M
T/O49.47MT/O Rate2.21%Tradable Shares81.38M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results
Benzinga  ·  05-14 02:07
These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results
Legend Biotech price target lowered to $48 from $49 at Morgan Stanley
TIPRANKS  ·  05-14 00:55
Legend Biotech price target lowered to $48 from $49 at Morgan Stanley
Legend Biotech Is Maintained at Outperform by RBC Capital
Dow Jones  ·  05-13 23:58
Legend Biotech Is Maintained at Outperform by RBC Capital
Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says
MT Newswires Live  ·  05-13 23:43
Legend Biotech Q1 Solid for Carvykti, Focus Shifts to In Vivo Pipeline, RBC Says
Legend Biotech price target raised to $64 from $62 at RBC Capital
TIPRANKS  ·  05-13 23:00
Legend Biotech price target raised to $64 from $62 at RBC Capital
RBC Lifts Price Target on Legend Biotech to $64 From $62, Keeps Outperform Rating
MT Newswires Live  ·  05-13 20:03
RBC Lifts Price Target on Legend Biotech to $64 From $62, Keeps Outperform Rating
Analysts Are Bullish on These Healthcare Stocks: AnaptysBio (ANAB), Legend Biotech (LEGN)
TIPRANKS  ·  05-13 19:40
Analysts Are Bullish on These Healthcare Stocks: AnaptysBio (ANAB), Legend Biotech (LEGN)
Barclays Reaffirms Their Buy Rating on Legend Biotech (LEGN)
TIPRANKS  ·  05-13 16:55
Barclays Reaffirms Their Buy Rating on Legend Biotech (LEGN)
Legend Biotech Corp : TD Cowen Raises Target Price to $29 From $21
THOMSON REUTERS  ·  05-13 13:50
Legend Biotech Corp : TD Cowen Raises Target Price to $29 From $21
GENSCRIPT BIO Surges Over 5% as Associate Legend Biotech Reports Narrowed Loss and Strong CARVYKTI® Sales Growth
Stock News  ·  05-13 09:38
GENSCRIPT BIO Surges Over 5% as Associate Legend Biotech Reports Narrowed Loss and Strong CARVYKTI® Sales Growth
Legend Biotech (LEGN) Valuation Check After Strong Revenue Growth And Narrowing Quarterly Loss
Simply Wall St.  ·  05-13 08:59
Legend Biotech (LEGN) Valuation Check After Strong Revenue Growth And Narrowing Quarterly Loss
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Tvardi Therapeutics (TVRD) and Organigram Global (OGI)
TIPRANKS  ·  05-13
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Tvardi Therapeutics (TVRD) and Organigram Global (OGI)
Legend Biotech Corp reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-12
Legend Biotech Corp reports results for the quarter ended March 31 - Earnings Summary
Legend Biotech reports Q1 EPS (3c), consensus (17c)
TIPRANKS  ·  05-12
Legend Biotech reports Q1 EPS (3c), consensus (17c)
Genscript flags Legend Biotech Q1 results and cautions investors on risk
TIPRANKS  ·  05-12
Genscript flags Legend Biotech Q1 results and cautions investors on risk
Legend Biotech Q1 2026 Results Show CARVYKTI-Fueled Revenue Surge and Narrowing Losses
TIPRANKS  ·  05-12
Legend Biotech Q1 2026 Results Show CARVYKTI-Fueled Revenue Surge and Narrowing Losses
Legend Biotech Q1 revenue slightly misses estimates
Reuters  ·  05-12
Legend Biotech Q1 revenue slightly misses estimates
Legend Biotech Q1 FY26 net loss narrows 46.24% to $54.3 million; revenue rises to $305.1 million
Reuters  ·  05-12
Legend Biotech Q1 FY26 net loss narrows 46.24% to $54.3 million; revenue rises to $305.1 million
Legend Biotech Q1 Adj. EPS $(0.03) Misses $(0.02) Estimate, Sales $305.100M Miss $307.035M Estimate
Benzinga  ·  05-12
Legend Biotech Q1 Adj. EPS $(0.03) Misses $(0.02) Estimate, Sales $305.100M Miss $307.035M Estimate
Legend Biotech Corp - Reports Cash and Cash Equivalents, Time Deposits of $834.6 Mln as of March 31, 2026
THOMSON REUTERS  ·  05-12
Legend Biotech Corp - Reports Cash and Cash Equivalents, Time Deposits of $834.6 Mln as of March 31, 2026

Introduction

Company Name.
Legend Biotech
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Legend Biotech Corp is a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's differentiated technology, global development and manufacturing strategy and expertise provide it with the ability to generate, test and manufacture next-generation cell therapies targeting indications with high unmet needs.
Issue price:
--